You're acting like you are Cochlear and you just created the...

You're acting like you are Cochlear and you just created the first hearing aid. NUH is entering a very established hearing loss market.

If any share price is too exuberant when it is in the gap between two different stages it has the ability to be reality checked. Luckily for NTI the SP is 20c and its whole mcap is only $20m. It still has room to move without being excessive.

If NTI did not sell product quick enough post FDA and if it burnt $4m per quarter like NUH Does with a $80m mcap it would have the ability to be reality checked in 12 months time. But NTI wont quadruple in mcap and it wont burn half what NUH does per quarter - due to sector differences. And if it does fly too high - fine reality check it!

This is not some competition - its meerly about recognising that if your mcap flys too high before it is making appropriate receipts and the company is at a stage where the market wants to start to see production stage outputs your SP may come back a bit.

NTI has not even released the results of their double blind study - so it is still being evaluated by development stage milestones.

NUH is past that point so unless your company can smoothly transition between development stage milestones and production stage output your SP and mcap will fall back a bit until it does. Most companies will not transition smoothly between the two stages so simply recognise that potentially coming back down to the 7c area is a possibility.

It is amazing what you can learn from markets when you are impartial.